Seismic Therapeutic
Joshua Vitlip has a diverse range of work experience. Joshua started their career as a Teaching Assistant at the University of Delaware in 2009. Joshua then worked as a Housewares Supervisor at Kohl's Department Stores from 2011 to 2013. Afterward, they held roles at Maynooth University as a Laboratory Assistant and Student from 2014 to 2017. Joshua then transitioned to WuXi Advanced Therapies, where they worked as a Laboratory Technician II from 2017 to 2018, a Laboratory Technician III from 2018 to 2020, and an Associate Scientist from 2020 to 2021. Next, they joined SQZ Biotechnologies as a Senior Research Associate from 2021 to 2022, and later as an Associate Scientist from 2022 to 2023. Currently, Joshua holds the position of Associate Scientist at Seismic Therapeutic starting from 2023. Throughout their career, they have gained experience in molecular and cell biology, in vivo studies, and the development of therapeutic options for autoimmune diseases.
Joshua Vitlip's education history begins with their Bachelor of Arts (B.A.) degree in Biology/Biological Sciences, General, which they obtained from the University of Delaware from 2007 to 2011. Joshua then pursued a Master of Science (M.Sc.) in Immunology and Global Health at Maynooth University between 2013 and 2014. Following this, they embarked on a Research Masters degree with a focus on Cellular Immunology at Maynooth University from 2015 to 2017.
Seismic Therapeutic
1 followers
Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using our IMPACT™ platform, we are addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to address adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub.